Adiposity-mortality relationships in type 2 diabetes, coronary heart disease and cancer subgroups in the UK Biobank, and their modification by smoking by Jenkins, David A. et al.
  
 
 
 
 
Jenkins, D. A., Bowden, J., Robinson, H. A., Sattar, N., Loos, R. J.F., Rutter, M. K. and 
Sperrin, M. (2018) Adiposity-mortality relationships in type 2 diabetes, coronary heart 
disease and cancer subgroups in the UK Biobank, and their modification by smoking. 
Diabetes Care, (doi:10.2337/dc17-2508). 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/165359/  
      
 
 
 
 
 
 
Deposited on: 01 August 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 - 1 - 
Adiposity-mortality relationships in type 2 diabetes, coronary heart disease and cancer 
subgroups in the UK Biobank, and their modification by smoking 
David A Jenkins1, Jack Bowden2, Heather A Robinson1, Naveed Sattar3, Ruth J.F. 
Loos4,5, Martin K Rutter6,7** and Matthew Sperrin1** 
1School of Health Sciences, Faculty of Biology, Medicine and Health, The University of 
Manchester, Oxford Road, Manchester, M13 9PL, U.K. 
2MRC Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, BS8 
2BN 
3Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK 
 
4The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at 
Mount Sinai, New York, NY 10029, USA  
5The Mindich Child Health Development Institute, Icahn School of Medicine at Mount Sinai, 
New York, NY 10029, USA  
6Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, 
Faculty of Biology, Medicine and Health, University of Manchester, Oxford Rd, Manchester, 
M13 9PL, UK. 
7Manchester Diabetes Centre, 193 Hathersage Rd, Manchester University NHS Foundation 
Trust, Manchester Academic Health Science Centre, Manchester, M13 0JE, UK. 
**Equal contribution 
  
*Corresponding author: David A Jenkins, Faculty of Biology, Medicine and Health, City Labs 
1.0, Nelson Street, University of Manchester, Manchester, M13 9NQ, email:david.jenkins-
5@manchester.ac.uk 
 - 2 - 
Key words: Obesity, body mass index, type 2 diabetes, coronary heart disease, smoking, 
mortality 
Abbreviations 
BMI: Body mass index 
OP: Obesity paradox 
CHD: Coronary heart disease 
 
Objective 
The obesity paradox, in which overweight/obesity is associated with mortality benefits, is 
believed to be explained by confounding and reverse causality, rather than a genuine clinical 
benefit of excess body weight. We aimed to gain deeper insights in the paradox through: 
analysing mortality relationships with several adiposity measures; assessing subgroups with 
type 2 diabetes, coronary heart disease (CHD) and smokers and by adjusting for several 
confounders. 
Research design and methods 
We studied the general UK Biobank population (n=502,631), along with 3 subgroups: 
individuals with a) type 2 diabetes (n=23,842); CHD (n=24,268) and c) cancer (n=45790) at 
baseline. A range of adiposity exposures were considered, including BMI (continuous and 
categorical), waist circumference, body fat percentage and waist-to-hip ratio, and the 
outcome was all-cause mortality. We used Cox regression models adjusted for age, smoking 
status, deprivation, education and disease history. 
Results 
For BMI, the obesity paradox was observed among people with type 2 diabetes (adjusted 
HR: obese vs. normal BMI: 0.78, 95% CI: 0.65,0.95), but not among those with CHD (HR: 
1.00: 0.86,1.17). The obesity paradox was pronounced in current smokers, absent in never 
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smokers, and more pronounced in men than women. For other adiposity measures, there 
was less evidence for an obesity paradox, yet smoking status consistently modified the 
adiposity-mortality relationships. 
Conclusions 
The obesity paradox was observed in people with type 2 diabetes and is heavily modified by 
smoking status. The results of sub-group analyses and statistical adjustments are consistent 
with reverse causality and confounding. 
Introduction 
The ‘obesity paradox’ refers to the commonly observed epidemiological finding that being 
overweight (body mass index (BMI) 25 to <30 kg/m2) or obese (BMI ≥30 kg/m2) is associated 
with longer survival than being normal weight1–3. This finding has been observed in patients 
with coronary heart disease (CHD)4, heart failure5, cancer6,7, and type 2 diabetes8–10, among 
many others.  The idea that being overweight or obese has survival advantages is contrary 
to known pathophysiological mechanisms linking obesity to adverse outcomes. The extent to 
which the paradox represents statistical biases11–13, versus genuine benefits of excess 
bodyweight, is of clear clinical importance.  
 The obesity paradox has been extensively explored with regards to BMI, but less 
often in relation to other measures of adiposity. BMI is an imprecise measure of body fat and 
we took the opportunity to relate additional measures of adiposity to mortality using the UK 
Biobank data14,15. The UK Biobank is an individual person health data resource with vast 
amounts of information, including variables that are potential confounders of relationships 
between adiposity measures and mortality.  
We therefore assessed the relationships between several measures of adiposity and 
mortality in a prospective cohort of UK Biobank participants, including subgroups with type 2 
diabetes, CHD and cancer. We also quantified the interaction effect of smoking status in 
these relationships. 
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Methods 
Study and disease subgroups 
The UK Biobank recruited 502,631 participants over the age of 40 years between 2006 and 
2010. All participants provided health, lifestyle and sociodemographic data through 
questionnaires and interviews, underwent physical examination, provided blood, urine and 
saliva samples and agreed to be followed for health outcomes. To facilitate follow-up, a wide 
range of databases, such as cancer and death registers, have been linked to UK Biobank.  
We studied the whole Biobank cohort and three subgroups. These subgroups were 
individuals with: i) type 2 diabetes defined using a validated algorithm16; ii) CHD, defined as 
participants with angina, myocardial infarction, coronary angioplasty/stent or coronary artery 
bypass surgery prior to recruitment; iii) cancer, as diagnosed in the cancer registry prior to 
UK Biobank assessment centre date.  
Assessment and classification of adiposity, confounders and outcomes 
Baseline questionnaires collected information on smoking status, ethnicity, education, 
disease history and other characteristics. Clinical examination by a nurse collected data on 
height, weight, body fat percentage and waist and hip circumference (methods described at 
http://biobank.ctsu.ox.ac.uk/crystal/).The deprivation score was calculated from postcode based 
on national census data. Incident cancer and all-cause mortality information were obtained 
from national registers linked to UK Biobank. 
BMI, calculated as weight (kg) divided by height (m) squared, was analysed both as 
a continuous variable, with a reference value of 22.5 kg/m2, and as a categorical variable 
based on the World Health Organisation (WHO) classifications where we split the 18.5 to 25 
category into two groups, as in previous literature9,17; categories: BMI <18.5, 18.5 to 22.4, 
22.5 to 24.9 (reference), 25.0 to 29.9, 30.0 to 39.9 and ≥40.0 kg/m2.  
Body fat percentage was estimated using bioelectrical impedance and treated as a 
continuous variable, with a reference obtained from WHO recommendations of 25% for men 
and 32% for women.  
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Waist circumference and waist-to-hip ratio (WHR) reference values for women were 
80cm and 0.85 respectively, and for men were 94cm and 0.9 respectively, based on the 
WHO classification and recommendations18. 
Smoking status was defined as a categorical variable with 4 categories: current 
smokers, past smokers, never smokers and unknown. 
Deaths were identified from the death register linked to the UK Biobank data; ICD10 
codes being used to identify the primary cause of death. Cancer deaths were defined as 
ICD10 codes C00-C97 and cardiovascular deaths as I00-I99, E10.5, E11.5, E12.5, E13.5 or 
E14.5. Deaths with other ICD10 codes as the primary cause of death were labelled as death 
for other causes. 
Statistical analyses 
The exposure was adiposity, assessed as BMI, body fat, waist circumference or WHR and 
the outcome was all-cause mortality. 
Survival analysis was conducted in the whole Biobank cohort and in diabetes, CHD 
and cancer subgroups separately, then further stratified by smoking (using the categories 
current, past and never smokers). 
We used Cox proportional hazard regression models with age as the timescale, left 
truncated at study entry, and the outcome was age at death recorded by the death register. 
All-cause mortality was the outcome for the primary analysis and the three cause specific 
mortalities were secondary outcomes. Individuals with no death recorded were censored at 
their attained age one month before the last death observed in the whole UK Biobank cohort 
to account for the potential lag time in recording deaths.  
Separate models were constructed for individual adiposity measures and these 
included cubic splines19 for continuous predictor variables, to provide the flexibility to identify 
any non-linear (e.g J-shape) relationships. Non-linearity was tested for by performing 
likelihood ratio tests and the best fitting model was chosen by assessing the Bayesian 
information criterion. We explored relationships between baseline adiposity measures and 
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time to death using: 1) unadjusted models; and 2) models adjusted for, age, sex, smoking 
status, ethnicity, education, deprivation index and chronic diseases (renal failure, liver 
failure, heart failure, dementia and cancer) diagnosed before study entry. Diabetes duration 
was not significantly related to mortality risk and was not included as a covariate. 
Proportionality was checked using Schoenfeld residuals, and models were stratified on 
variables that were found to violate proportionality. The BMI associated with the lowest 
mortality was obtained as the BMI value with the smallest hazard ratio, with bootstrapped 
confidence intervals. 
We considered the obesity paradox to be present in a cohort if a BMI value greater 
than 25 kg/m2 or adiposity measure above the reference value was associated with 
significantly longer survival than its reference.  
The modifying effect of smoking on the paradox was also tested by including a 
smoking interaction with adiposity. 
Data analysis was performed using STATA (Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP) and R (version 3.4.2). P<0.05 was considered 
statistically significant. 
Results 
Baseline characteristics 
The final cohort comprised 229,170 men and 273,461 women. A total of 212,166 individuals 
(42%) were overweight, of which 47% are women, whereas the underweight and most 
obese BMI categories were made up of predominantly women; 79% and 63%, respectively 
(Table 1). The highest percentage of smokers (23%) was observed among the underweight 
(BMI<18.5 kg/m2) compared with 10% among the obese individuals. Data on BMI, %body 
fat, waist circumference and WHR were available in 99%, 98%, 99% and 99% of participants 
respectively. 
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A total of 13,502 (56.6%) of the 23,842 individuals with type 2 diabetes and 9,704 
(40%) of the 24,268 individuals with CHD were obese. The remaining baseline 
characteristics had comparable proportions across BMI categories.  
A total of 14,421 deaths were observed over a mean follow-up of 7.8 years. Of those 
who died, 1,723 (11.9%) had type 2 diabetes, 2,004 (13.9%) had CHD and 3,212 (22.2%) 
had cancer recorded at baseline. Cancer and cardiovascular related deaths amounted to 
57.5% (8,286) and 20.8% (2,998) of all deaths, respectively. 
Relationships between BMI categories and mortality  
In all groups, we observed U-shaped relationships between BMI categories and mortality 
(figure 1). Among all UK Biobank participants, being underweight was associated with higher 
mortality risk than normal weight. This association was stronger among men (HR: 3.28 [CI, 
2.62 to 4.11]) than in women (HR: 1.72 [CI: 1.37 to 2.16]; p-value for interaction: <0.001) in 
the overall population.   
Morbidly obese individuals (>= 40 kg/m2) had higher mortality than normal weight in 
the overall population, but not in the type 2 diabetes or women with CHD subgroups. 
In people with type 2 diabetes, being obese was associated with lower mortality than 
being normal weight (HR: 0.78 [CI, 0.65 to 0.95]), and this appeared to be driven by a lower 
hazard in men with type 2 diabetes (HR: 0.74 [CI, 0.60 to 0.92]), while women with type 2 
diabetes did not have a statistically lower mortality risk (HR: 1.13 [CI, 0.73 to 0.1.75]). 
Hence, in the categorical analyses the obesity paradox was present only in men with type 2 
diabetes. 
Compared with normal-weight individuals, being overweight was associated with a 
lower mortality risk only in men with type 2 diabetes (HR: 0.74 [CI, 0.59 to 0.92]).  
Relationships between continuous BMI and all-cause mortality  
Consistent with the categorical BMI data, we observed a U-shaped relationship between BMI 
and all-cause mortality among all groups (Figure 2); low and high BMI values were 
associated with higher mortality than a BMI of 22.5 kg/m2. Within the whole UK Biobank 
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population, the lowest mortality was observed at a BMI of 27.2 kg/m2 (mortality HR: 0.83 [CI, 
0.80 to 0.86]; referent BMI: 22.5 kg/m2; supplementary table ST1), whereas among 
individuals with type 2 diabetes, the BMI with the lowest mortality risk was much higher 
(women: 34.1 kg/m2; men: 31.7 kg/m2). Among those with CHD, lowest mortality rates were 
observed at 29.4 kg/m2 in women and 29.9 kg/m2 in men. 
Effect of smoking on relationships between continuous BMI and mortality 
In men, the obesity paradox was evident in smokers, but not in non-smokers (p-interaction: 
0.002; figure 3). The paradox was still present in men who had previously smoked, but to a 
lesser extent than the current smokers. In particular, obese smokers had lower mortality than 
normal-weight smokers. In contrast, obese non-smokers had higher mortality than normal-
weight non-smokers and only those in the overweight range had lower mortality. In all 
women, however, there was no evidence of the obesity paradox.  
In smokers and ex-smokers with type 2 diabetes, cancer or CHD, obese (or 
overweight) individuals had lower mortality than normal weight individuals. However, in 
current smokers the association with lower mortality was more pronounced and included 
those with higher BMI values. In never smokers with cancer, there was no evidence of an 
obesity paradox. Other important confounding factors in the data included: age, ethnicity and 
renal and heart failure (see supplementary table ST2). 
Relationships between continuous BMI and cause specific mortality  
Similar relationships were observed when considering death by cancer and death from other 
causes (supplementary figures SF4 and SF6). For cardiovascular death, some sub-groups 
(all participants; women only; smokers with diabetes) showed similar results to those of the 
BMI-all cause mortality analysis but differences were observed in other sub-groups 
(supplementary figure SF5). The obesity paradox did not appear to be present in these other 
sub-groups and although smoking still appeared to modify the relationship, it was not as 
influential as observed in the all-cause mortality analysis and other cause-specific mortality 
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analyses. Larger confidence intervals were also observed in the CVD mortality results, due 
to lower event rates or larger heterogeneity. 
Body fat percentage and all-cause mortality  
In keeping with the BMI results, we observed U-shaped relationships between body fat 
percentage and mortality. Among all participants, and subgroups with type 2 diabetes or 
CHD, low (<20%) and very high (>45%) body fat percentage were significantly associated 
with higher mortality, except in women with type 2 diabetes and CHD in whom some high 
percentage body fat values were not associated with a different mortality than those with 
32% body fat. However for current smokers, only the subgroups of all men and men with 
prior cancer showed a significant increase in mortality for very high fat percentages (Figure 
3).  
The percentage body fat associated with the minimum mortality in men and women 
was 24.5% and 36.1%, respectively. In men with type 2 diabetes, CHD or cancer, the 
minimum mortality was associated with numerically higher percent body fat values (type 2 
diabetes: 29.2%; CHD: 27.7%; cancer: 25.2%) than in the whole male subgroup, but these 
risks were not significantly lower than the risk associated with the reference percentage body 
fat value of 25%. In women with type 2 diabetes, CHD or cancer, the minimum mortality risk 
was associated with higher percentage body fat values (type 2 diabetes: 44.3%; CHD: 
39.5%; cancer: 37%) than in the whole female subgroup, and only in women with type 2 
diabetes were these values not associated with a lower mortality compared to the reference 
value of 32%. 
Waist circumference and all-cause mortality risk 
Similar U-shaped relationships were observed between waist circumference and 
mortality (supplementary figure SF2). However, the paradox was only observed in men with 
CHD. In all women, and in women with CHD, high waist, but not low waist circumference, 
was associated with a higher mortality than the reference value (85cm). In women with type 
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2 diabetes, mortality did not significantly vary by waist circumference when compared with 
the referent group. 
Waist-to-hip ratio (WHR) and all-cause mortality risk 
Only men with CHD had similar adiposity and mortality relationships as seen with the 
previous adiposity measures (supplementary figure SF3). In men with type 2 diabetes, there 
was a suggestion of a U-shaped relationship but only high WHR values were significantly 
associated with higher mortality compared to reference values in previous smokers. 
For men and women in the ‘all participants’ group, relationships between WHR and 
mortality risk were positive and demonstrated a more linear relationship (supplementary 
figure S3). In women with type 2 diabetes, cancer or CHD, individuals with low WHR values 
had a similar mortality risk to women with reference values. In women with CHD, high WHR 
values were associated with a higher mortality risk than referent, but this was only observed 
in the current and past smokers. In women with type 2 diabetes, cancer and never smokers 
with CHD, mortality risks were not statistically different to referent.  
Sensitivity analyses 
We performed several sensitivity analyses: 1) Analysing categorical BMI according to the 
WHO categories only, and not further splitting the 18.5-25 category, had some small effect 
on our results (data not shown). In men, being obese was no longer associated with higher 
mortality than the reference group (BMI: 18.5-24.9) and being overweight was associated 
with lower mortality than the reference. The only other observed differences were in the 
overweight categories where some of the subgroups (all participants, participants with type 2 
diabetes, participants with CHD and men with CHD) were now observed to have a 
statistically significantly lower mortality than the reference group. For all other subgroups, the 
WHO categorisation did not affect our results. 2) Excluding patients who died within one year 
of study entry did not substantively alter our conclusions. 3) When we excluded patients with 
type 2 diabetes, CHD, or cancer, from the whole population, our results and conclusions did 
not differ substantively from the original analyses (data not shown). 
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Discussion  
Main findings 
This large cohort study provides several original observations: 1), even after adjusting for 
several potential confounders, the relationship between BMI and mortality was U-shaped 
with a minimum risk for mortality in the overweight range (BMI: 27.2 kg/m2); 2) the obesity 
paradox was observed in men and women with type 2 diabetes with the minimum mortality 
risk in the obese range (women with type 2 diabetes: 34.1 kg/m2; men with type 2 diabetes: 
31.7 kg/m2) whereas in men and women with CHD, the minimum risk was in the overweight 
range; 3) smoking exaggerated the U-shaped relationship between BMI and mortality by in-
creasing the relative risk in normal-weight and underweight individuals compared to over-
weight and obese participants - as previously described in CHD20; 4) U-shaped relationships 
between measures of adiposity and mortality were less apparent using body fat percentage, 
waist circumference and waist-hip ratios but the influence of smoking on these relationships 
was similar to that seen in BMI-mortality relationships.  
Previous studies 
Several other studies in diabetes and CHD cohorts have observed the obesity paradox. Most 
of these only consider a single disease subgroup, such as those with diabetes. Only the 
French E3N EPIC study20 and the study by Badrick et al9 analysed the obesity paradox in 
subgroups with and without diabetes. Both studies identified the obesity paradox and 
Badrick et al found that that smoking as an effect modifier explained the paradox (p-
interaction: p=0.009). For example, the HR (95% CI) for mortality associated with BMI values 
30-35 kg/m2 in smokers with diabetes was 0.72 (0.56 to 0.92) compared with normal weight 
participants9. These papers were, however, limited in sample size and did not use any other 
measure of adiposity apart from BMI. For example, Badrick et al studied only 1795 smokers 
with diabetes9. 
In type 2 diabetes, the look AHEAD trial21 did not show CVD or mortality benefits 
through weight loss22. Observational studies of intentional weight loss have provided 
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conflicting results and can be prone to bias. For example, a study in people with type 2 
diabetes23,24 suggested that intentional weight loss was associated with increased mortality 
compared with stable weight individuals, but the influence of reverse causality from diseases 
causing pathological weight loss is difficult to exclude. Other observational studies25 in type 2 
diabetes and in the general population have suggested mortality benefits through intentional 
weight loss. 
Bownam et al showed that having a high waist circumference and being normal 
weight or overweight (defined by BMI) was associated with substantial excess mortality25. 
Although Bowman’s study involved UK Biobank participants, it focussed on the interaction 
between WHR and BMI on mortality and it was limited by considering BMI only as a 
categorical variable; studying participants aged 60-69 years and having a sample size of 
130,473.  
The EPIC cohort20,26 was the largest study to explore the obesity paradox in a 
general population of 359,387 participants using multiple measures of adiposity and found 
both BMI and central adiposity measures were both associated with mortality risk. The EPIC 
study had limited data on individuals with BMI >35 kg/m2 and it only included ‘healthy 
individuals’ after excluding those with history of cancer, heart disease, or stroke.  
Mechanistic insights 
BMI, as a construct, is limited because it conflates lean mass and fat mass. Individuals with 
low BMI will generally have a low fat mass which might be expected to have some health 
advantages. However, low BMI is also linked to low muscle mass which could be a marker of 
serious underlying disease and frailty. Similarly, there will be some fit and healthy individuals 
with high BMI who have high muscle mass and low fat mass. As such, BMI is an imperfect 
proxy for adiposity. 
In our analysis, smoking significantly influenced the shape of relationships between 
BMI and mortality such that, among smokers, individuals with low BMI appeared to have 
higher mortality than overweight and obese individuals. Although this relationship persisted 
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after adjusting for the presence of known disease, undiagnosed serious smoking-related 
diseases, such as chronic obstructive pulmonary disease and lung cancer, could partly 
explain the obesity paradox through confounding and reverse causation.  
Our assessment of body fat enabled us to assess the individual contribution of low 
body fat to mortality. The U-shaped relationships observed suggest that low body fat per se 
is generally associated with higher mortality than individuals with normal or higher body fat 
percentage. Although we adjusted for several important confounders, our analysis is unable 
to differentiate between the presence of a genuine causal relationship between low body fat 
and higher mortality and the influence of residual confounding from unmeasured variables. 
We observed strongest evidence for the obesity paradox in participants with type 2 
diabetes. A plausible explanation for this is that participants with type 2 diabetes would have 
a higher likelihood of being obese than other groups27. In these people, weight-losing chronic 
illness (linked to higher mortality), would have a greater tendency to lead to a BMI reduction 
into the normal BMI range rather than into the underweight BMI range, which would be a 
more likely scenario in the general population. Prospective cohort studies comparing BMI 
changes during terminal illnesses in people with and without diabetes could test this 
hypothesis. 
Strengths and limitations 
Our study has several strengths: 1) it involved a large prospective cohort with high-quality 
baseline including data on several potential confounders in the relationship between BMI 
and mortality; 2) we considered several adiposity measures (BMI, %fat mass, waist circum-
ference and waist-hip ratio) which enabled us to separate relationships of lean mass and fat 
mass with mortality risk; 3) we considered BMI as a categorical exposure and as a continu-
ous variable which enabled us to establish cohort-specific adiposity values associated with 
the lowest mortality risks; 4) we assessed relationships in the whole cohort in addition to 
three groups in which the obesity paradox has been described previously (those with CHD, 
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cancer and type 2 diabetes); 5)Objectively measured body weight and body fat were used, 
which are less error prone than questionnaire-based self-reports. 
We acknowledge some limitations: 1) although we adjusted for many variables that 
minimised the potential for cofounding, we cannot rule out the role of unmeasured con-
founders. Confounding can also be amplified by collider stratification bias where obesity is 
itself a risk factor for the incident disease13; 2) UK Biobank participants are a relatively 
healthy cohort and may not be fully representative of the UK population28; 3) although the 
data were rich, all exposures and confounders were assessed at baseline only. Therefore, 
adiposity levels assessed after diagnosis of a disease such as diabetes may have been in-
fluenced by the effects of that disease and/or clinical interventions; 4) all participants were 
UK-based, middle-aged or elderly and so extrapolation of findings to different cohorts should 
be done with a degree of caution29; 5) although participant numbers were high, disease sub-
groups (type 2 diabetes and CHD) were smaller, leading to larger confidence intervals and 
lower statistical power, particularly in women. 
Clinical implications 
These observational data confirm prior research findings27 and provide further mechanistic 
insights but cannot provide clinical guidance regarding the potential risks or benefits of 
weight loss in the general population or in diseased groups. Such clinical guidance can only 
come from randomised controlled trials. 
Conclusion 
Even after adjusting for potential confounders, there were strong U-shaped relationships be-
tween several measures of adiposity and mortality risk. We showed strong evidence of the 
obesity paradox in individuals with type 2 diabetes and that smoking modifies relationships 
between BMI and mortality. Analysis using body fat percentage and waist circumference al-
so demonstrated U-shaped relationships with mortality risk, but did not show evidence of an 
obesity paradox. These data provide further insights into potential mechanisms linking adi-
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posity and mortality, and deepen our understanding of the obesity paradox. However, further 
research is required to understand the true causal nature of these relationships before clini-
cal guidance is modified.  
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Table 1 
  BMI categories 
Characteristics <18.5 18.5-22.49 22.5-24.9 25-29.9 30-39.9 >40 
No of participants 2626 
(0.52) 
59538 
(11.85) 
102909 
(20.47) 
212166 
(42.21) 
112581 
(22.4) 
12811 
(2.55) 
Female 2079 
(79.17) 
43980 
(73.87) 
61709 
(59.96) 
99904 
(47.09) 
57682 
(51.24) 
8107 
(63.28) 
Age (years)* 55.47 
(8.16) 
54.9 (8.27) 56.13 (8.17) 57.01 (8.06) 56.97 (7.89) 55.69 
(7.85) 
Ethnicity       
White European 2438 
(92.84) 
56372 
(94.68) 
97516 
(94.76) 
200043 
(94.29) 
105354 
(93.58) 
11091 
(86.57) 
South Asian 44 (1.68) 808 (1.36) 1661 (1.61) 3543 (1.67) 1666 (1.48) 345 (2.69) 
African Caribbean 10 (0.38) 453 (0.76) 1042 (1.01) 3257 (1.54) 2777 (2.47) 526 (4.11) 
Mixed or other 112 (4.27) 1657 (2.78) 2272 (2.21) 4342 (2.05) 2160 (1.92) 364 (2.84) 
Deprivation * -0.67 
(3.41) 
-1.36 (3.07) -1.57 (2.96) -1.44 (3.02) -0.9 (3.23) 0.09 (3.46) 
Education       
College or 
University degree  
1059 
(40.33) 
25105 
(42.17) 
38668 
(37.57) 
65967 
(31.09) 
27561 
(24.48) 
2845 
(22.21) 
Smoking       
Never 1474 
(56.13) 
35883 
(60.27) 
59747 
(58.06) 
113066 
(53.29) 
56883 
(50.53) 
6543 
(51.07) 
Previous 540 
(20.56) 
15923 
(26.74) 
31893 
(30.99) 
76322 
(35.97) 
43994 
(39.08) 
4422 
(34.52) 
Current 598 
(22.77) 
7529 
(12.65) 
10842 
(10.54) 
21693 
(10.22) 
10969 (9.74) 1358 (10.6) 
Chronic diseases       
Hyperlipidemia 11 (0.42) 263 (0.44) 765 (0.74) 2788 (1.31) 2412 (2.14) 331 (2.58) 
Renal failure 47 (1.79) 386 (0.64) 715 (0.69) 2187 (1.03) 2041 (1.81) 478 (3.73) 
Liver failure 4 (0.15) 35 (0.06) 56 (0.05) 143 (0.07) 116 (0.1) 7 (0.05) 
Heart failure 47 (1.79) 432 (0.73) 824 (0.8) 2633 (1.24) 2589 (2.3) 574 (4.48) 
Dementia 8 (0.3) 125 (0.21) 212 (0.21) 473 (0.22) 292 (0.26) 51 (0.4) 
Cancer 306 (11.7) 5806 (9.75) 9657 (9.38) 18827 (8.87) 10066 (8.94) 1128 (8.8) 
Diabetes 29 (1.1) 573 (0.96) 1745 (1.7) 7993 (3.77) 11146 (9.9) 2356 
(18.39) 
CHD 55 (2.09) 1128 (1.89) 2898 (2.82) 10483 (4.94) 8621 (7.66) 1083 (8.45) 
Values are numbers and percentage unless otherwise stated 
* Values are mean (SD)  
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Table and figure legends 
Table 1: Baseline characteristics by BMI category 
 
Figure 1: Adjusted hazard ratios (95% CI) for all-cause mortality in relation to BMI categories 
at baseline with BMI 22.5-24.9 as referent 
 
Figure 2: Adjusted hazard ratios (95% CI) for all-cause mortality associated with BMI by 
smoking status (never smokers = NS, previous smoker = PS and current smokers = CS) in 
men and women and by CHD, type 2 diabetes and cancer status at baseline with BMI 22.5 
as referent* 
* Models are adjusted for, age, smoking status (current, past and never), ethnicity, educa-
tion, deprivation index and chronic diseases diagnosed before study entry 
 
Figure 3: Adjusted hazard ratios (95% CI) for all-cause mortality associated with body fat 
percentage by smoking status (never smokers = NS, previous smoker = PS and current 
smokers = CS) in men and women and by CHD, type 2 diabetes and cancer status at 
baseline with BMI 22.5 as referent* 
* Models are adjusted for, age, smoking status (current, past and never), ethnicity, educa-
tion, deprivation index and chronic diseases diagnosed before study entry 
 
<18.5
All participants
-    Men
-    Women
Participants with type 2 diabetes
-    Men with type 2 diabetes
-    Women with type 2 diabetes
Participants with CHD
-    Men with CHD
-    Women with CHD
Participants with cancer
-    Men with cancer
-    Women with cancer
18.5-22.49
All participants
-    Men
-    Women
Participants with type 2 diabetes
-    Men with type 2 diabetes
-    Women with type 2 diabetes
Participants with CHD
-    Men with CHD
-    Women with CHD
25-29.9
All participants
-    Men
-    Women
Participants with type 2 diabetes
-    Men with type 2 diabetes
-    Women with type 2 diabetes
Participants with CHD
-    Men with CHD
-    Women with CHD
Participants with cancer
-    Men with cancer
-    Women with cancer
30-39.9
All participants
-    Men
-    Women
Participants with type 2 diabetes
-    Men with type 2 diabetes
-    Women with type 2 diabetes
Participants with CHD
-    Men with CHD
-    Women with CHD
Participants with cancer
-    Men with cancer
-    Women with cancer
≥40
All participants
-    Men
-    Women
Participants with type 2 diabetes
-    Men with type 2 diabetes
-    Women with type 2 diabetes
Participants with CHD
-    Men with CHD
-    Women with CHD
Participants with cancer
-    Men with cancer
-    Women with cancer
ID
Study
2.32 (1.97, 2.72)
3.28 (2.62, 4.11)
1.72 (1.37, 2.16)
4.18 (2.04, 8.57)
3.82 (1.55, 9.43)
5.90 (1.76, 19.76)
3.39 (1.97, 5.84)
3.61 (1.83, 7.11)
2.93 (1.16, 7.42)
2.40 (1.74, 3.30)
3.59 (2.06, 6.28)
2.32 (1.57, 3.44)
1.20 (1.12, 1.28)
1.33 (1.21, 1.46)
1.09 (0.99, 1.19)
1.20 (0.88, 1.64)
1.27 (0.88, 1.83)
1.43 (0.78, 2.65)
1.40 (1.12, 1.76)
1.56 (1.21, 2.03)
1.04 (0.65, 1.66)
0.97 (0.93, 1.02)
0.96 (0.90, 1.02)
1.01 (0.93, 1.08)
0.82 (0.68, 1.00)
0.74 (0.59, 0.92)
1.13 (0.73, 1.75)
0.89 (0.77, 1.04)
0.92 (0.77, 1.09)
0.80 (0.56, 1.13)
1.07 (0.97, 1.18)
1.00 (0.86, 1.15)
1.05 (0.91, 1.20)
1.11 (1.05, 1.17)
1.11 (1.04, 1.19)
1.10 (1.02, 1.20)
0.78 (0.65, 0.95)
0.74 (0.60, 0.92)
1.00 (0.65, 1.52)
1.00 (0.86, 1.17)
1.00 (0.84, 1.19)
1.03 (0.74, 1.44)
1.35 (1.22, 1.51)
1.39 (1.19, 1.62)
1.23 (1.06, 1.42)
1.83 (1.68, 2.00)
1.98 (1.76, 2.23)
1.60 (1.40, 1.82)
0.96 (0.76, 1.20)
1.10 (0.84, 1.44)
1.10 (0.69, 1.76)
1.44 (1.15, 1.80)
1.51 (1.17, 1.96)
1.21 (0.77, 1.89)
1.97 (1.62, 2.39)
2.42 (1.81, 3.25)
1.80 (1.39, 2.34)
ES (95% CI)Population Adjusted HR (95% CI)
  
1.5 1.5 2 2.5 3 3.5 4 4.5 5


